retatrutide and heart issues Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Retatrutide and Cardiovascular Risk: Evaluating

But how do they work

Ozempic and Mounjaro are not FDA-approved to treat obesity or for weight loss

Some evidence-based supplements do pair well with GLP-1 medications

From their beginnings as a treatment for type 2 diabetes, GLP-1 receptor agonists such as the semaglutide drugs Ozempic and Wegovy and the tirzepatide drugs Mounjaro and Zepbound have seen an explosion in use, most popularly for weight loss

However, churn can operate in both directions

GIPR activation produces: Additional glucose-dependent insulin secretion (synergistic with GLP-1R on -cells) Direct effects on adipocyte (fat cell) lipid metabolism, including enhanced lipid uptake and storage dynamics paradoxically, this appears to contribute to improved metabolic outcomes by improving adipose tissue function rather than simply increasing fat storage Bone metabolism regulation GIPR is expressed in osteoblasts and osteoclasts and influences bone turnover (research area) Central nervous system effects via hypothalamic GIPR that are distinct from but complementary to GLP-1R appetite circuits The synergy between GIPR and GLP-1R at the -cell level amplifies insulin secretion beyond what either receptor achieves alone